All the news Showing 10 of 3,034 articlesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sex between men Widespread PrEP use is not leading to more hepatitis C transmission among gay and bisexual men Keith Alcorn / 03 August 2022 The incidence of hepatitis C infection is now four times lower in gay and bisexual PrEP users than it was before direct-acting antivirals for the treatment of hepatitis C became ... HBV treatment for people with HIV Biktarvy combination pill may be most effective option for people with HIV and hepatitis B Liz Highleyman / 03 August 2022 Although two antiretroviral drug regimens proved about equally effective at suppressing HIV, the Biktarvy combination pill (bictegravir, emtricitabine and tenofovir alafenamide) did a better job suppressing hepatitis B virus (HBV) ... Screening policy New NHS programme to find and cure hidden Hepatitis C NHS England / 03 August 2022 Likely cause of mystery child hepatitis outbreak found BBC / 25 July 2022 Treatment for people who use drugs Peer-led recruitment improves hepatitis C screening in people who use drugs Keith Alcorn / 25 July 2022 A peer-led recruitment strategy proved highly successful in engaging people who use drugs in testing and treatment for hepatitis C in the French city of Montpellier, researchers from the University of Montpellier report ... Kidney disease & HCV Higher kidney disease risk persists in people cured of hepatitis C Keith Alcorn / 19 July 2022 People with hepatitis C remain at higher risk of chronic kidney disease after clearing or being cured of hepatitis C and people with genotype 1 infection have a higher risk of kidney ... Starting treatment Why do people with HIV delay hepatitis C treatment? Keith Alcorn / 15 July 2022 Greater efforts by healthcare providers to build trusting relationships with people with HIV and hepatitis C, together with a greater focus on overcoming concerns about treatment side effects, are likely to be needed ... New and experimental treatments for hepatitis B Bepirovirsen suppresses hepatitis B surface antigen, moves forward to larger functional cure studies Keith Alcorn / 29 June 2022 Bepirovirsen, an experimental drug with a novel mode of action, suppressed hepatitis B surface antigen below the limits of detection in approximately 30% of patients after 24 weeks of treatment and ... Hepatitis D Bulevirtide leads to sustained improvement for people with hepatitis D Liz Highleyman / 28 June 2022 The entry inhibitor bulevirtide (Hepcludex) led to a reduction in hepatitis delta virus (HDV) viral load, lower liver enzyme levels and improvement in fibrosis after 48 weeks of follow-up, according to findings ... New and experimental treatments for hepatitis B Experimental hepatitis B combination suppresses key marker but fails to achieve functional cure Keith Alcorn / 27 June 2022 People with hepatitis B who received a combination of experimental drugs as well as their standard treatment for 48 weeks were significantly less likely to have high levels of hepatitis B surface ... ← Prev12345...304Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive